Estrogen Dose Equivalence: Patch, Gel, Spray and Pill Compared

Why an equivalence table exists at all

If your usual estradiol patch is unavailable, or a side effect pushes you to change route, the first question is always the same: what dose of the new form matches the dose I am on now? There is a published answer, and it is worth understanding its limits before you use it.

The standard comparison

The most widely cited equivalence in menopause practice lines up three products at what trials found to be comparable relief of hot flashes and night sweats:

The KEEPS trial compared oral conjugated estrogens 0.45 mg/day against a 50 mcg/day patch directly and found similar relief of vasomotor symptoms, which is one reason clinicians treat this row as a working reference rather than a precise conversion.

The Canadian Menopause Society publishes a systemic MHT equivalency table covering more products, and it is the kind of document worth taking to an appointment.

Why these are approximations, not conversions

These numbers come from clinical trials that produced similar symptom relief. They are not pharmacokinetic equivalents, and the difference matters.

Swallowed estrogen passes through the liver before reaching the rest of the body. The liver metabolizes a large share of it and, in the process, raises production of clotting factors and of sex hormone binding globulin. A patch, gel or spray delivers estradiol through the skin straight into the circulation and skips that pass. So two "equivalent" doses can produce the same number of hot flashes per day while behaving differently in the bloodstream.

Two practical consequences:

• Route affects clot risk. Transdermal estrogen has not shown the same venous thromboembolism signal as oral estrogen in observational data, which is why it is often preferred for women with migraine with aura, obesity, or a personal or family clot history.
• Route affects your lab results. Oral estrogen raises sex hormone binding globulin, which lowers free testosterone even when total testosterone looks normal. If you have been told your testosterone is fine but you feel otherwise, the route you take estrogen by is part of that picture.

Gel, spray and ring

Equivalence for gels and sprays is less standardized than for patches, because absorption depends on application site, surface area and how much of the product actually stays on the skin. Manufacturers publish the estradiol content per pump or sachet, but the resulting blood level varies more between people than a patch does. Practically, this means a switch to gel or spray is usually made by choosing a starting dose from the product label and adjusting on symptoms after several weeks, not by arithmetic from your patch strength.

Vaginal rings are a separate case: a low-dose ring treats local genitourinary symptoms and does not deliver a systemic dose, while a higher-dose systemic ring does. These are not interchangeable, and confusing them is a common error during a supply disruption.

Progestogen is not optional if you have a uterus

Changing your estrogen form does not change the rule that systemic estrogen given to a woman with an intact uterus requires a progestogen to protect the endometrium. The FDA kept the endometrial cancer warning on systemic estrogen-alone products even while removing the other boxed warnings in 2026. If a supply problem forces a change, the progestogen part of the regimen has to be reviewed at the same time, not left on autopilot.

What to ask at the appointment

• "My patch is 50 mcg. If we move to gel or spray, what starting dose do you want, and when do we reassess?"
• "Does this change affect my progestogen dose or schedule?"
• "Given my clot and migraine history, is there a reason to stay transdermal?"
• "If the shortage eases, do I switch back or stay on the new form?"

Low, standard and high dose

Clinicians usually think in bands rather than exact milligrams. The 50 mcg patch sits in the middle band, which is why it is used as the reference point in the table above.

Starting low and reviewing is the usual approach, but "lowest effective dose" means the lowest dose that actually controls your symptoms, not the lowest dose on the shelf. Under-treatment is as much a failure as over-treatment, and it is the more common one in practice.

Why blood levels are a poor way to steer this

Women frequently ask for an estradiol level to confirm their dose is right. It is a weaker tool than it sounds:

• Levels from patches and gels fluctuate with application site, skin, and time since application.
• There is no agreed target level for symptom control — the therapeutic range for menopause is defined by how you feel, not by a number.
• Standard immunoassays perform poorly at the low concentrations found in postmenopausal women.

Levels do have a place: checking absorption when a woman on an adequate dose still has full symptoms, or when a patch appears not to be working at all. As a routine dose-titration tool, symptoms are the better guide.

Vaginal estrogen is a separate conversation

Low-dose vaginal estrogen — cream, tablet or low-dose ring — treats genitourinary symptoms locally, with minimal systemic absorption. It does not appear on the equivalence table because it is not doing the same job: it will not touch hot flashes and it does not protect bone. It can be used alongside systemic therapy, or on its own by women who only have vaginal and urinary symptoms.

Confusing a low-dose vaginal ring with a systemic ring is a genuine error during a supply disruption, and the two are not interchangeable.

How long a switch takes to judge

Give a new form four to eight weeks before deciding. Vasomotor symptoms usually respond within a few weeks; sleep and mood often follow more slowly; vaginal symptoms can take several months on local treatment. Judging a change after ten days produces unnecessary switching.

A note on transdermal and clot risk

The observation that transdermal estrogen has not shown the venous thromboembolism signal associated with oral estrogen comes from observational data rather than a large randomised trial designed to answer it. It is consistent, it has a clear biological explanation in first-pass liver metabolism, and it is reflected in how clinicians choose routes — but it is worth knowing the strength of the evidence behind a recommendation you may be given.